Composite Interventions on Outcomes of Severely and Critically Ill Patients with COVID-19 in Shanghai, China
Jiasheng Shao, Rong Fan, Chengnan Guo, Xuyuan Huang, Runsheng Guo, Fengdi Zhang, Jianrong Hu, Gang Huang, Liou Cao
Microorganisms, doi:10.3390/microorganisms11071859
Background: The sixty-day effects of initial composite interventions for the treatment of severely and critically ill patients with COVID-19 are not fully assessed. Methods: Using a Bayesian piecewise exponential model, we analyzed the 60-day mortality, health-related quality of life (HRQoL), and disability in 1082 severely and critically ill patients with COVID-19 between 8 December 2022 and 9 February 2023 in Shanghai, China. The final 60-day follow-up was completed on 10 April 2023. Results: Among 1082 patients (mean age, 78.0 years, 421 [38.9%] women), 139 patients (12.9%) died within 60 days. Azvudine had a 99.8% probability of improving 2-month survival (adjusted HR, 0.44 [95% credible interval, 0.24-0.79]), and Paxlovid had a 91.9% probability of improving 2-month survival (adjusted HR, 0.71 [95% credible interval, 0.44-1.14]) compared with the control. IL-6 receptor antagonist, baricitinib and a-thymosin each had a high probability of benefit (99.5%, 99.4%, and 97.5%, respectively) compared to their controls, while the probability of trail-defined statistical futility (HR > 0.83) was high for therapeutic anticoagulation (99.8%; HR, 1.64 [95% CrI, 1.06-2.50]) and glucocorticoid (91.4%; HR, 1.20 [95% CrI,). Paxlovid, Azvudine, and therapeutic anticoagulation showed a significant reduction in disability (p < 0.05) Conclusions: Among severely and critically ill patients with COVID-19 who received 1 or more therapeutic interventions, treatment with Azvudine had a high probability of improved 60-day mortality compared with the control, indicating its potential in a resource-limited scenario. Treatment with an IL-6 receptor antagonist, baricitinib, and a-thymosin also had high probabilities of benefit in improving 2-month survival, among which a-thymosin could improve HRQoL. Treatment with Paxlovid, Azvudine, and therapeutic anticoagulation could significantly reduce disability at day 60.
Conflicts of Interest: The authors declare no conflict of interest.
References
Abdelhady, Abdelrazik, Abdi, Abdo, Abdulle et al., Effect of Convalescent Plasma on Organ Support-Free Days in Critically Ill Patients With COVID-19: A Randomized Clinical Trial, JAMA,
doi:10.1001/jama.2021.18178
Bellet, Renga, Pariano, Stincardini, D'onofrio et al., COVID-19 and beyond: Reassessing the role of thymosin alpha1 in lung infections, Int. Immunopharmacol,
doi:10.1016/j.intimp.2023.109949
Bolek, Samos, Jurica, Stanciakova, Pec et al., COVID-19 and the Response to Antiplatelet Therapy, J. Clin. Med,
doi:10.3390/jcm12052038
Bradbury, Lawler, Stanworth, Mcverry, Mcquilten et al., Effect of Antiplatelet Therapy on Survival and Organ Support-Free Days in Critically Ill Patients With COVID-19: A Randomized Clinical Trial, JAMA,
doi:10.1001/jama.2022.2910
Chinese Thoracic, Chinese Association Of Chest, Critical, Group, Expert consensus on treatment of severe COVID-19 caused by Omicron variants, Zhonghua Jie He He Hu Xi Za Zhi,
doi:10.3760/cma.j.cn112147-20221230-00994
Cilloniz, Motos, Castaneda, Gabarrus, Barbe et al., Remdesivir and survival outcomes in critically ill patients with COVID-19: A multicentre observational cohort study, J. Infect,
doi:10.1016/j.jinf.2022.12.027
Dyer, COVID-19: China stops counting cases as models predict a million or more deaths, BMJ,
doi:10.1136/bmj.p2
Ely, Ramanan, Kartman, De Bono, Liao et al., Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: An exploratory, randomised, placebo-controlled trial, Lancet Respir. Med,
doi:10.1016/S2213-2600(22)00006-6
Florescu, Stanciu, Zaharia, Kosa, Codreanu et al., Long-term (180-Day) Outcomes in Critically Ill Patients With COVID-19 in the REMAP-CAP Randomized Clinical Trial, JAMA,
doi:10.1001/jama.2022.23257
Goligher, Bradbury, Mcverry, Lawler, Berger et al., Therapeutic Anticoagulation with Heparin in Critically Ill Patients with COVID-19, N. Engl. J. Med,
doi:10.1056/NEJMoa2103417
Group, Horby, Lim, Emberson, Mafham et al., Dexamethasone in Hospitalized Patients with COVID-19, N. Engl. J. Med,
doi:10.1056/NEJMoa2021436
Huang, Li, Gu, Zhang, Ren et al., Health outcomes in people 2 years after surviving hospitalisation with COVID-19: A longitudinal cohort study, Lancet Respir. Med,
doi:10.1016/S2213-2600(22)00126-6
Ioannidis, Zonta, Levitt, Estimates of COVID-19 deaths in Mainland China after abandoning zero COVID policy, Eur. J. Clin. Investig,
doi:10.1111/eci.13956
Jimenez-Mora, Varela, Meneses-Echavez, Bidonde, Angarita-Fonseca et al., Patient-important outcomes reported in randomized controlled trials of pharmacologic treatments for COVID-19: A protocol of a META-epidemiological study, Syst. Rev,
doi:10.1186/s13643-021-01838-8
Liu, Pan, Hu, Wu, Wang et al., Thymosin Alpha 1 Reduces the Mortality of Severe Coronavirus Disease 2019 by Restoration of Lymphocytopenia and Reversion of Exhausted T Cells, Clin. Infect. Dis,
doi:10.1093/cid/ciaa630
Liu, Pan, Zhang, Li, Ma et al., Efficacy and safety of Paxlovid in severe adult patients with SARS-Cov-2 infection: A multicenter randomized controlled study, Lancet Reg. Health West Pac,
doi:10.1016/j.lanwpc.2023.100694
Liu, Zhang, Lu, Li, Wu et al., Benefits of high-dose intravenous immunoglobulin on mortality in patients with severe COVID-19: An updated systematic review and meta-analysis, Front. Immunol,
doi:10.3389/fimmu.2023.1116738
Martinez-Guerra, Gonzalez-Lara, Roman-Montes, Tamez-Torres, Dardon-Fierro et al., Outcomes of patients with severe and critical COVID-19 treated with dexamethasone: A prospective cohort study, Emerg. Microbes. Infect,
doi:10.1080/22221751.2021.2011619
Salehi, Barkhori Mehni, Akbarian, Fattah Ghazi, Khajavi Rad et al., The outcome of using intravenous immunoglobulin (IVIG) in critically ill COVID-19 patients': A retrospective, multi-centric cohort study, Eur. J. Med. Res,
doi:10.1186/s40001-022-00637-8
Shao, Fan, Hu, Zhang, Lee et al., Clinical Progression and Outcome of Hospitalized Patients Infected with SARS-CoV-2 Omicron Variant in Shanghai, China, Vaccines,
doi:10.3390/vaccines10091409
Wan, Wang, Mathur, Chan, Yan et al., Molnupiravir and nirmatrelvir-ritonavir reduce mortality risk during post-acute COVID-19 phase, J. Infect
Wang, Yu, Yu, Wang, Chen et al., Clinical features and outcomes of hospitalized patients with COVID-19 during the Omicron wave in Shanghai, China, J. Infect,
doi:10.1016/j.jinf.2022.08.001
Xu, Fan, Wang, Zou, Yu et al., Suppressed T cell-mediated immunity in patients with COVID-19: A clinical retrospective study in Wuhan, China, J. Infect,
doi:10.1016/j.jinf.2020.04.012
Yu, Chang, The first Chinese oral anti-COVID-19 drug Azvudine launched, Innovation
Zhang, Li, Wang, Liu, Lu et al., Azvudine is a thymus-homing anti-SARS-CoV-2 drug effective in treating COVID-19 patients, Signal. Transduct. Target Ther,
doi:10.1038/s41392-021-00835-6